Plasmid

PTC Therapeutics Celebrates Opening of Gene Therapy Manufacturing Facility

Thursday, October 14, 2021 - 1:30pm

SOUTH PLAINFIELD, N.J., Oct. 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc.(NASDAQ: PTCT) will host a ribbon-cutting ceremony to recognize the official opening of its new gene therapy manufacturing facility in Hopewell, N.J. today at 4 p.m.

Key Points: 
  • SOUTH PLAINFIELD, N.J., Oct. 14, 2021 /PRNewswire/ -- PTC Therapeutics, Inc.(NASDAQ: PTCT) will host a ribbon-cutting ceremony to recognize the official opening of its new gene therapy manufacturing facility in Hopewell, N.J. today at 4 p.m.
  • "We are committed to being an innovation-based company that brings the best therapies to patients with rare diseases," said Stuart W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics.
  • We have built our capabilities to both perform gene therapy research and to manufacture these biological products.
  • The Hopewell gene therapy manufacturing center complements PTC's existing operations at the Company's global headquarters in South Plainfield, N.J. and brings the total number of New Jersey-based employees to 625.

M6P Therapeutics to Present at the 17th Annual International Congress on Neuronal Ceroid Lipofuscinosis

Friday, October 8, 2021 - 12:30pm

Neuronal ceroid lipofuscinosis type 2 (CLN2) is a neurodegenerative disorder caused by autosomal recessive mutations in the TPP1 gene, leading to the deficiency of TPP1, a lysosomal enzyme.

Key Points: 
  • Neuronal ceroid lipofuscinosis type 2 (CLN2) is a neurodegenerative disorder caused by autosomal recessive mutations in the TPP1 gene, leading to the deficiency of TPP1, a lysosomal enzyme.
  • Batten disease originally referred specifically to the juvenile and most common form of neuronal ceroid lipofuscinosis (NCL), now known as CLN3 .
  • Most forms are inherited in an autosomal recessive manner; however, autosomal dominant inheritance has been reported in one adult-onset form (neuronal ceroid lipofuscinosis 4B).
  • M6P Therapeutics mission is to translate advanced science into best-in-class therapies that address unmet needs within the LSD community.

Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medical

Monday, September 27, 2021 - 1:00pm

Alan Wirbisky, Director of Device Development at Eyevensys, said: The opportunity to collaborate with both Minnetronix Medical and Phillips-Medisize is incredibly significant for Eyevensys given the capabilities and experience that the two companies possess.

Key Points: 
  • Alan Wirbisky, Director of Device Development at Eyevensys, said: The opportunity to collaborate with both Minnetronix Medical and Phillips-Medisize is incredibly significant for Eyevensys given the capabilities and experience that the two companies possess.
  • During our 25 year history, we have successfully partnered with many medical startups like Eyevensys to navigate the pitfalls of electromechanical medical device development.
  • Since 1996, Minnetronix Medical has accelerated medical device breakthroughs via design, development and manufacturing services for companies around the world.
  • Minnetronix Medical is based in St. Paul, Minn. More information can be found on the Minnetronix website, by calling 651-917-4060 or emailing info@minnetronixneuro.com .

$8.4 Bn CRISPR Markets - Global Forecasts from 2021 to 2026: Escalating R&D to Provide Opportunities Market Players - ResearchAndMarkets.com

Tuesday, September 21, 2021 - 12:25pm

The global CRISPR market is a growing with major investments from developed countries.

Key Points: 
  • The global CRISPR market is a growing with major investments from developed countries.
  • The growing need for drug research, the risk of congenital abnormalities, and late pregnancies resulting in birth problems are key factors driving the CRISPR market forward.
  • The escalating geriatric population, Changes in lifestyles, and investment in cutting-edge research technologies are also augmenting the market size.
  • A lot of research and development happening in the market is anticipated to boost the opportunities through the inclining market trends.

Secondcell Bio Publishes Biotechnology for Improved Drug Discovery Originating from The Rockefeller University

Wednesday, September 15, 2021 - 3:00pm

"Little more than a random and highly inefficient enterprise, drug discovery today is "garbage in, garbage out" enterprise.

Key Points: 
  • "Little more than a random and highly inefficient enterprise, drug discovery today is "garbage in, garbage out" enterprise.
  • Currently, the industry average failure rate for drug discovery programs in pharmaceutical companies is reported to be approximately 98%.
  • This work was performed by Chromocell Corporation, a biotechnology company spun out of The Rockefeller University based upon the technology.
  • Secondcell, Secondcell Bio, Cellbrary, Cellbraries, Chromo-Plasmid, pChromo-Plasmid, Chromo-Tag, Drugomics, Drug Discovery at Scale, and the Secondcell Bio logo are trademarks of Secondcell Bio, LLC.

AGC Biologics Expands pDNA and mRNA Manufacturing Capacity at Heidelberg Facility

Tuesday, September 14, 2021 - 12:57am

Heidelberg, Germany, Sept. 13, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced expansion plans for the companys Heidelberg facility to increase manufacturing capacities for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects.

Key Points: 
  • Heidelberg, Germany, Sept. 13, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced expansion plans for the companys Heidelberg facility to increase manufacturing capacities for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects.
  • With this expansion, AGC Biologics is boosting its current 100L and 1,000L manufacturing capacities for a variety of different biologics projects by adding an additional GMP manufacturing line.
  • This investment helps strengthen our existing pDNA capabilities and supports our entry into the mRNA space, says AGC Biologics Chief Executive Officer, Patricio Massera.
  • These new capacities will help strengthen our Heidelberg facility, says AGC Biologics Heidelberg Site Head, Dieter Kramer.

TriAltus Bioscience Granted U.S. Patent for CL7 Tag Technology

Wednesday, August 25, 2021 - 3:12pm

BIRMINGHAM, Ala., Aug. 25, 2021 /PRNewswire/ -- TriAltus Bioscience announced that the U.S Patent and Trademark Office has issued U.S. Patent No 10,759,830 for its CLM affinity tag system, which delivers proteins with ultra-high purity and yield in a single step.

Key Points: 
  • BIRMINGHAM, Ala., Aug. 25, 2021 /PRNewswire/ -- TriAltus Bioscience announced that the U.S Patent and Trademark Office has issued U.S. Patent No 10,759,830 for its CLM affinity tag system, which delivers proteins with ultra-high purity and yield in a single step.
  • The patent, entitled "Bacterial colicin-immunity protein purification system," covers mutations made to colicin E7, a naturally occurring e.coli protein, making it suitable for use as a novel tag.
  • This patent will help TriAltus to develop its CLM system, and explore new applications including membrane purification, vaccine delivery, and biofuel production.
  • Having proven the CLM technology on some extremely difficult proteins, TriAltus is now developing R&D partnerships to use CLM to purify proteins for customer-defined projects.

AGC Biologics Announces the Groundbreaking of its New Facility at its Copenhagen, Denmark Site

Friday, August 20, 2021 - 6:39pm

COPENHAGEN, Aug. 20, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announces the groundbreaking of its new facility at its Copenhagen, Denmark site.

Key Points: 
  • COPENHAGEN, Aug. 20, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announces the groundbreaking of its new facility at its Copenhagen, Denmark site.
  • This multipurpose facility will allow AGC Biologics to increase its capacity and space to accommodate new and existing clients needs.
  • This new expansion will allow AGC Biologics to generate around 250-300 new workplaces in Denmark.
  • We are excited to announce the groundbreaking of the new facility, said AGC Biologics CEO Patricio Massera.

Zydus receives EUA from DCGI for ZyCoV-D, the only needle-free COVID vaccine in the world

Friday, August 20, 2021 - 6:47pm

ZyCoV-D is a three dose vaccine which will be administered first on day zero, day 28th and then on the 56th day.

Key Points: 
  • ZyCoV-D is a three dose vaccine which will be administered first on day zero, day 28th and then on the 56th day.
  • With this approval, India now has its first COVID-19 vaccine for the adolescents in the 12-18 age group, besides the adult population.
  • ZyCoV-D, is a needle-free vaccine administered using The PharmaJet a needle free applicator, which ensures painless intradermal vaccine delivery.
  • This is for the first time that a technologically advanced vaccine has been successfully developed on the Plasmid DNA platform for human use.

AGC Biologics Appoints Tony Fraij as the new General Manager/Site Head of the Longmont, Colorado Site

Monday, August 9, 2021 - 6:00pm

Effective August 9, 2021, Tony Fraij will join the Longmont team as General Manager/Site Head.

Key Points: 
  • Effective August 9, 2021, Tony Fraij will join the Longmont team as General Manager/Site Head.
  • Mr. Fraij will oversee the leadership of the Longmont site as it gets integrated into the AGC Biologics global facility network.
  • His proven leadership skills and commitment to excellence will be greatly embraced in Longmont and across the AGC Biologics global network.
  • We are excited to add Tony as another talented leader within the AGC Biologics organization.